Stem Cell Research Laboratory, Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Leukemia. 2011 Sep;25(9):1408-14. doi: 10.1038/leu.2011.108. Epub 2011 May 27.
Many in vitro and in vivo data are available supporting the role of mesenchymal stromal cell (MSC) licensing in the induction of a measurable and effective immune regulation. The failure of some MSC-based protocols for immune modulation in animal models and in human clinical trials may be explained by either lack of a proper licensing by inflammatory microenvironment or wrong timing in MSC administration. Thus, optimization of MSC use for immune-regulating purposes is required to maximize their beneficial effects.
有许多体外和体内数据支持间充质基质细胞（MSC）许可在诱导可测量和有效的免疫调节中的作用。一些基于 MSC 的免疫调节方案在动物模型和人类临床试验中失败，可能是由于炎症微环境缺乏适当的许可或 MSC 给药时间错误所致。因此，需要优化 MSC 的使用以达到免疫调节目的，从而最大限度地发挥其有益作用。
